# Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

> **NCT03351569** · PHASE3 · UNKNOWN · sponsor: **Azienda Socio Sanitaria Territoriale di Mantova** · enrollment: 1 (actual)

## Conditions studied

- Unverricht-Lundborg Disease

## Interventions

- **DRUG:** Intravenous immunoglobulin

## Key facts

- **NCT ID:** NCT03351569
- **Lead sponsor:** Azienda Socio Sanitaria Territoriale di Mantova
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12-09
- **Primary completion:** 2016-12-06
- **Final completion:** 2017-12-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351569, "Intravenous Immunoglobulin for Unverricht-Lundborg Disease.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03351569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*